跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
VPI-AMIKACIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
VPI-AMIKACIN
Authorized
STANDARD
VPI-AMIKACIN
VPI Pharmaceuticals Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
923d83a7f865cd4a
Company
VPI Pharmaceuticals Inc
Type
Standard
Approval Details
Approval Id
923d83a7f865cd4a
Drug Approval Canada Name
VPI-AMIKACIN
Product Name
VPI-AMIKACIN
Status
Dormant
Status Date
2023-07-13
Original Market Date
2021-01-25
Din
02506599
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intramuscular , Intravenous
Schedule
Prescription
Ahfs
08:12.02
Atc Original
J01GB06 AMIKACIN
Atc Name
j 01 gb 06
Aig Number
0111922001
Company Name
VPI Pharmaceuticals Inc
Company Address
16667 Hymus Boulevard, Kirkland, Quebec, Canada, H9H 4R9
Company Detail Path
/organization/vpi-pharmaceuticals-inc
Company Information
Pharmaceutical Company Name
VPI Pharmaceuticals Inc
Country Name
Canada
Province Name
Quebec
City Name
kirkland,quebec,country_ca
Address
16667 boul Hymus
Active Ingredients
AMIKACIN (AMIKACIN SULFATE)
500 MG / 2 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
923d83a7f865cd4a
Type
Standard
Back to Health Canada Approvals